Impact of Neratinib on CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer: Analysis of Data From Phase II/III Trials

December 10-14, 2019; San Antonio, Texas
In patients with HER2+ breast cancer and CNS metastases, use of neratinib-based therapy showed CNS activity in this combined analysis of 3 clinical trials.
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: December 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Prof. Dr. Arndt Hartmann Released: April 9, 2021

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer in a webcast presented by Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Experts discuss their practices with CDK4/6 and PI3K inhibitors for patients with breast cancer in today’s clinic from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Downloadable short slideset from CCO on the use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue